LAUSR

Small‐molecule splicing modulators exemplified by an FDA‐approved drug, risdiplam, are a new pharmacological modality for regulating the expression and stability of splice isoforms. We report a CRISPR‐mediated enzyme fragment complementation (EFC) assay to quantify the splice isoform stability. The EFC assay harnessed a 42 amino acid split of a β‐galactosidase (designate α‐tag), which could be fused at the termini of the target genes using CRISPR/cas9. The α‐tagged splice isoform would be quantified by measuring the enzymatic activity upon complementation with the rest of β‐galactosidase. This EFC assay retained all the sequences of introns and exons of the target gene in the native genomic environment that recapitulates the cell biology of the diseases of interest. For a proof‐of‐concept, we developed a CRISPR‐mediated EFC assay targeting the exon 7 of the survival of motor neuron 2 (SMN2) gene. The EFC assay is compatible with 384‐well plates and robustly quantified the splicing modulation activity of small molecules. In this study, we also discovered that a coumarin derivative, compound 4, potently modulated SMN2 exon 7 splicing at as low as 1.1 nM.